Osteoporosis Management in the Era of COVID‐19. (26th May 2020)

• Record Type: Journal Article
• Authors: Yu, Elaine W; Tsourdi, Elena; Clarke, Bart L; Bauer, Douglas C; Drake, Matthew T
• Is Part Of: Journal of bone and mineral research. Volume 35:Number 6(2020)
• Page Start: 1009
• Page End: 1013
• Publication Date: 2020-05-26
• Subjects: ABALOPARATIDE -- BISPHOSPHONAT -- COVID‐19 -- DENOSUMAB -- FRACTURES -- OSTEOPOROSIS -- ROMOSOZUMAB -- TERIPARATIDE; Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.4049
• Languages: English
• ISSNs: 0884-0431

Abstract

ABSTRACT: Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID‐19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID‐19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. © 2020 American Society for Bone and Mineral Research.